Bristol Myers Squibb (BMY) News Today

Bristol Myers Squibb logo
$61.32 -1.61 (-2.56%)
Closing price 03:59 PM Eastern
Extended Trading
$61.06 -0.26 (-0.42%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Why Is Bristol Myers Squibb Down Today?

Bristol Myers Squibb Company (NYSE: BMY) received a potential pipeline boost from a new clinical collaboration, while the reported news offers no clear company-specific explanation for recent share weakness.

  • Positive Sentiment: Bristol Myers will sponsor a Phase 1/2 study testing Erasca’s ERAS-0015 with BMS’s navlimetostat in patients with MTAP-deleted pancreatic cancer; Erasca will supply ERAS-0015. The partnership could advance a combination approach in a difficult-to-treat cancer, although it remains early-stage and no financial terms or clinical results were disclosed. Erasca clinical collaboration announcement
  • Positive Sentiment: Barclays reaffirmed its Buy rating on BMY, indicating continued analyst confidence, though the report provided no new clinical or financial catalyst in the supplied details. Barclays rating report
  • Neutral Sentiment: Revolution Medicines received European approval for Rasonque in metastatic pancreatic cancer. This adds a competing treatment in the broader indication, but the article does not establish a direct impact on BMS’s investigational combination. Rasonque EU approval report
  • Neutral Sentiment: BMY was described as a trending stock, reflecting investor attention rather than a new business development or a clear explanation for its trading direction. BMY trending-stock report

Takeaway: The collaboration and Barclays’ rating are supportive, but the trial is at an early stage. The items provided do not identify a material negative BMY-specific catalyst that would explain the stock’s decline.

Posted 2h agoAI Generated. May Contain Errors.

Bristol Myers Squibb Latest News

Erasca announces agreement with Bristol Myers
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
Barclays Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
BMY Stock Gets Stronger EPS Estimate from Zacks Research
Zacks Research Has Weak Estimate for BMY FY2026 Earnings
Bristol Myers to operate R&D under one organization
Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

Bristol Myers Squibb Media Mentions By Week

Bristol Myers Squibb Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BMY
News Sentiment
▼
0.36

0.56
▲
Average
Healthcare
News Sentiment

Bristol Myers Squibb News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BMY Articles
This Week
▼
36

9
▲
BMY Articles
Average Week

Bristol Myers Squibb Trends on MarketBeat

This week vs. last week
New Followers
1
Searches
11
+38%
Page Views
4,390
-38%
Get Bristol Myers Squibb News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Bristol Myers Squibb dated 11/17/2026.
From Our Partners